Odylia CEO, Scott Dorfman, speaks at NIH/FDA Gene Therapy Manufacturing meeting
Bethesda, MD-January 29th, 2020 – Odylia founder and CEO, Scott Dorfman, recently spoke at the The National Institutes o...
About Odylia
Our Path
Resources
Consortium
What we do
Odylia Therapeutics is a non-profit corporation working to bring treatments for rare eye disease from the lab into humans using genetic therapies. Today, there are more than 300 known genetic forms of Inherited Retinal Disease (IRD) that lead to blindness, with some of these interfering with other sensory mechanisms like hearing and balance. Most are extremely rare, impacting less than one in a million people worldwide.
Why we exist
Although pre-clinical proof-of-concept treatments exist for some of these diseases, because they are so rare, there is little commercial interest in them. Odylia was formed to find a way to move these potential therapies into clinical trials to protect and restore the vision of those going blind.
Why we exist
Although pre-clinical proof-of-concept treatments exist for some of these diseases, because they are so rare, there is little commercial interest in them. Odylia was formed to find a way to move these potential therapies into clinical trials to protect and restore the vision of those going blind.
Latest news
Stay up-to-date with our research and clinical trials
-
-
Meet with Odylia at JP Morgan Healthcare Conference
Representatives from Odylia Therapeutics will be at the JP Morgan Healthcare Conference in San Francisco in January. We&...
-
Ashley Winslow joins Nonprofit Biotech Odylia Therapeutics as Chief Scientific Officer
Atlanta, GA November 4, 2019 – Ashley Winslow, Ph.D, joins Odylia Therapeutics as Chief Scientific Officer. ...